Once More Unto The Breach: 2014 NME Candidates Crowd In Familiar Fields
Executive Summary
With new drug candidates concentrated in already-crowded markets like diabetes, anti-thrombotics and oncology, in 2014 sponsors must be prepared to demonstrate value not just to regulators but to payers as well. Merck, Lilly and AstraZeneca account for one-third of pending novel agents as the companies seek to recover from the patent cliff.